Emmaus Life Sciences (EMMA) Short Interest Ratio & Short Volume

Short interest is the volume of Emmaus Life Sciences shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 6,400 shares of EMMA short. 0.02% of Emmaus Life Sciences' shares are currently sold short. Learn More on Emmaus Life Sciences' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.02% of Emmaus Life Sciences' floating shares are currently sold short.

Emmaus Life Sciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 6,400 shares, an increase of 30.6% from the previous total of 4,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.02% of Emmaus Life Sciences' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Emmaus Life Sciences: Kazia Therapeutics Limited (2.32%), Clearmind Medicine Inc. (6.53%), Adial Pharmaceuticals, Inc. (8.50%), Aptorum Group Limited (0.96%), Creative Medical Technology Holdings, Inc. (1.46%), Allarity Therapeutics, Inc. (14.12%), Portage Biotech Inc. (8.44%), GRI Bio, Inc. (3.69%), Sonnet BioTherapeutics Holdings, Inc. (1.70%), Azitra, Inc. (4.84%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks.

Short selling EMMA is an investing strategy that aims to generate trading profit from Emmaus Life Sciences as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Emmaus Life Sciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of EMMA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EMMA, twice per month. The most recent reporting period available is March, 15 2025.